Albumin Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 7.27 Billion |
| Market Size (2029) | USD 10.56 Billion |
| CAGR (2024 - 2029) | 7.76 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Albumin Market Analysis
The Albumin Market size is estimated at USD 7.27 billion in 2024, and is expected to reach USD 10.56 billion by 2029, growing at a CAGR of 7.76% during the forecast period (2024-2029).
The outbreak of COVID-19 had a significant impact on the market since albumin infusion was widely used for COVID-19-infected patients. Also, albumin was reported as an important marker for predicting COVID-19. For instance, according to the article published in October 2022 in PubMed, albumin administration was found to regulate COVID-19-related biomarkers and reduce the risk of death in critical patients with hypoalbuminemia. Thus, the pandemic significantly impacted the studied market due to the increase in the adoption of albumin treatments for COVID-19-infected patients. However, in the post-pandemic scenario, with the declining COVID-19 cases, the studied market is anticipated to grow considerably due to the rise in research and development activities using albumin and the improvements in therapeutics for various diseases.
The major factors attributed to the growth of the albumin market include the rise in non-therapeutic applications of albumin and the high demand for albumin in R&D activities. For instance, as per an article published in April 2023 in Frontiers Journal, albumin-based hydrogels demonstrated significant progress in antitumor-drug delivery and tissue regeneration engineering. Due to the controlled mechanical properties, better biocompatibility and better degradability, albumin-based products are utilised by researchers for studies. Moreover, the launch of new products and strategic partnerships by the key players in the market is expected to address the growing need for albumin in addressing many chronic conditions, thereby driving the market. For instance, in January 2022, Bio Products Laboratory (BPL), a manufacturer of plasma-derived protein therapies, received National Medical Products Administration (NMPA) license to market ALBUMINEX 25% product to China. ALBUMINEX treats hypovolemia (a condition that occurs when the body loses fluid, like blood or water), ascites, hypoalbuminemia and burns. As albumin effectively reverses hypovolemia, such strategic product launches are likely to increase the demand for albumin products, thereby contributing to market growth over the forecast period.
Furthermore, rising research and development activities and clinical studies demonstrating the advantages of albumin are also expected to boost the market. For instance, in February 2023, Ruijin Hospital sponsored a clinical trial to compare the effects of different amounts of human albumin infusion per week in patients with hospitalised decompensated cirrhosis on 28-day transplant-free survival and to compare further the alleviation of inflammation, reduction of incidence of nosocomial infection, spontaneous bacterial peritonitis (SBP), acute kidney injury (AKI), acute-on-chronic liver failure (ACLF), and 90-day transplant-free survival.
Hence, owing to the increase in clinical studies and the rise in strategic activities by the key payers, the studied market is expected to grow significantly. However, irrational uses and adverse reactions associated with albumin and the rising shift toward serum-free solutions are expected to hinder market growth during the forecast period.
Albumin Market Trends
The Human Serum Albumin Segment is Expected to Witness a Notable Growth in the Studied Market Over the Forecast Period
Human serum albumin (HSA) is the serum albumin found in human blood and is the most available protein in human blood plasma. As one of the most abundant proteins in blood plasma, human serum albumin facilitates the transport of hormones, fatty acids and various compounds through the bloodstream. Also, HSA helps in maintaining osmotic blood pressure in the body. Human serum albumin is utilised under multiple clinical conditions, such as restoration of blood volume, emergency treatment of shock, acute management of burns, and other situations associated with hypovolemia, and hence, they are in high demand worldwide.
Factors such as an increase in hypovolemia conditions due to various chronic diseases, a rise in utilisation of human serum albumin in intensive care units, and an increase in HSA product launches by the key players are expected to fuel the segment growth over the forecast period. For instance, cancer patients are likely to be hypovolemic due to continuous vomiting and diarrhoea or inadequate intake of fluids. An increase in cancer cases is expected to raise the demand for HSA, bolstering market growth. For instance, according to the American Cancer Society 2023 Cancer Statistics, about 1.93 million cancer cases are estimated to be reported in 2023 in the United States. The high burden of cancer is expected to augment the demand for HSA, thereby boosting segment growth over the forecast period.
Furthermore, the presence of key players and their strategic activities like product launches, collaborations and agreements are likely to raise the availability and demand for the HSA over the forecast period. For instance, in November 2021, Grifols launched its latest albumin portfolio innovation, ALBUTEIN FlexBag (Albumin [Human] U.S.P.), in 5% and 25% concentrations. Furthermore, an increase in research studies demonstrating the advantages the HSA offers in various therapies will likely contribute to the market growth over the forecast period. For instance, as per the article published in February 2023 in the RSC Advances journal, the researchers demonstrated that compared with individual chemotherapy or photodynamic therapy (PDT) nanoplatforms, hollow human serum albumin had a better anticancer effect via the combination of PDT with chemotherapy after loading photosensitiser Ce6 and anticancer drug DOX. Hence, with such advances and benefits offered by the HSA in chronic disease treatment, the studied segment is expected to grow significantly over the forecast period. Additionally, hypoalbuminemia is considered one of the significant indications of protein-calorie malnutrition and chronic liver disease. Thus, an increase in research funding related to nutrition can include the research and development support of various HSA products, which is expected to augment the segment growth over the study period.
Thus, due to the increase in the adoption of HSA in chronic disease treatment, and the rise in strategic product launches by the key players coupled with benefits offered by the HSA in drug delivery, the studied segment is expected to witness notable market growth over the forecast period.
North America is Expected to Witness a Significant Growth Over the Forecast Period
The North American region is expected to witness healthy growth over the forecast period, owing to the presence of key market players and their strategic activities, the rise in cancer cases, which leads to hypoalbuminemia and a surge in research and development activities to develop albumin-based products.
The increase in liver cancer among the North American population is on the rise, which is expected to raise the demand for HSA, as hepatic cell carcinoma patients with lower serum albumin levels had significantly larger maximum tumour diameters compared to higher albumin level patients. For instance, according to the Canadian Cancer Society, 3,500 Canadians were diagnosed with liver cancer in 2022. These cancers mainly affect adults and are more common in men than women. Further, according to a study published in March 2022 in PubMed, hypoalbuminemia was an independent risk factor for tumour progression in early-stage, non-ablative hepatocellular carcinoma (HCC). Thus, the high prevalence of HCC is expected to bolster the demand for albumin-based products, which is further likely to augment the market growth in North America over the forecast period.
Moreover, strategic activities by the key players, such as product launches, partnerships, acquisitions, and rising investments, are further expected to drive the market as these activities are likely to increase the availability of albumin products across the North American region. For instance, in July 2022, EKF Diagnostics revealed the availability of the FDA-cleared Lucica Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corp. and sold exclusively in the United States by EKF. Lucica Glycated Albumin-L is a specific, quantitative glycated albumin test for intermediate-term glycemic control monitoring in patients with diabetes. It is an enzymatic method for compatible clinical chemistry analysers with open channel capability.
Thus, due to the high prevalence of chronic disease, which requires albumin-based treatment and the rise in strategic product launches by the key players, North America is expected to witness significant market growth over the forecast period.
Albumin Industry Overview
The albumin market is fairly competitive and consists of several key market players. In terms of market share, few of the major players currently dominate the market. With the rising need for better healthcare treatments and the increasing prevalence of diseases, a few other smaller players are expected to enter the market. Some of the key players in the albumin market are Akron Biotech, Baxter International Inc., Bristol-Myers Squibb Company, Biotest AG, and Merck KGaA, among others.
Albumin Market Leaders
-
Baxter International Inc.
-
Bristol-Myers Squibb Company
-
Merck KGaA
-
Grifols (Biotest AG)
-
Thermo Fisher Scientific
*Disclaimer: Major Players sorted in no particular order
Albumin Market News
- In March 2023, Albumedix and Heartseed presented Recombumin as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first-in-human trial launched. Recombumin, an animal and human-origin-free recombinant albumin, is an excipient in the final formulation of Heartseed's HS-001 treatment.
- In September 2022, the life science group Sartorius, through its French-listed subgroup Sartorius Stedim Biotech acquired Albumedix Ltd, a key player in recombinant albumin-based solutions based in Nottingham, United Kingdom.
Albumin Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 High Demand for Albumin in R&D Activities
- 4.2.2 Rise in Non-therapeutic Applications of Albumin
- 4.2.3 Rising Production of Immunoglobulin
-
4.3 Market Restraints
- 4.3.1 Irrational Uses and Adverse Reactions Associated with Albumin
- 4.3.2 Rising Shift toward Serum-free Solutions
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD Million)
-
5.1 By Type
- 5.1.1 Human Serum Albumin
- 5.1.2 Bovine Serum Albumin
- 5.1.3 Recombinant Albumin
-
5.2 By Application
- 5.2.1 Drug Delivery
- 5.2.2 Therapeutics
- 5.2.3 Culture Media Ingredient
- 5.2.4 Vaccine Ingredient
- 5.2.5 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Akron Biotech
- 6.1.2 Baxter International Inc.
- 6.1.3 Grifols (Biotest AG)
- 6.1.4 Bristol-Myers Squibb Company
- 6.1.5 Merck KGaA
- 6.1.6 Novozymes AS
- 6.1.7 Octapharma AG
- 6.1.8 CSL Behring
- 6.1.9 Medxbio Pte Ltd
- 6.1.10 China Biologic Products Holdings Inc.
- 6.1.11 Thermo Fisher Scientific
- 6.1.12 Albumedix Ltd
- 6.1.13 Ventria Bioscience Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAlbumin Industry Segmentation
As per the scope of the report, albumin is a water-soluble globular protein produced in the liver and accounts for 50% of blood plasma proteins. It plays a vital role in regulating blood volume and is a transporter for molecules, such as hormones, bile salts, and ions. It is commonly used as a blood volumiser in rare diseases, burns, shocks, liver conditions, and other blood loss trauma and surgeries. The Albumin Market is Segmented by Type (Human Serum Albumin, Bovine Serum Albumin, and Recombinant Albumin), Application (Drug Delivery, Therapeutics, Culture Media Ingredient, Vaccine Ingredient, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Type | Human Serum Albumin | |
| Bovine Serum Albumin | ||
| Recombinant Albumin | ||
| By Application | Drug Delivery | |
| Therapeutics | ||
| Culture Media Ingredient | ||
| Vaccine Ingredient | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Albumin Market Research FAQs
How big is the Albumin Market?
The Albumin Market size is expected to reach USD 7.27 billion in 2024 and grow at a CAGR of 7.76% to reach USD 10.56 billion by 2029.
What is the current Albumin Market size?
In 2024, the Albumin Market size is expected to reach USD 7.27 billion.
Who are the key players in Albumin Market?
Baxter International Inc., Bristol-Myers Squibb Company, Merck KGaA, Grifols (Biotest AG) and Thermo Fisher Scientific are the major companies operating in the Albumin Market.
Which is the fastest growing region in Albumin Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Albumin Market?
In 2024, the North America accounts for the largest market share in Albumin Market.
What years does this Albumin Market cover, and what was the market size in 2023?
In 2023, the Albumin Market size was estimated at USD 6.71 billion. The report covers the Albumin Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Albumin Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
What are the cost considerations for entering the Albumin Market?
The cost considerations for entering the Albumin Market are a) Evaluating manufacturing infrastructure b) Production costs c) Potential pricing strategies
What are the cost considerations for entering the Albumin Market?
The cost considerations for entering the Albumin Market are a) Evaluating manufacturing infrastructure b) Production costs c) Potential pricing strategies
Albumin Industry Report
The global albumin market is experiencing substantial growth, driven by the increasing prevalence of conditions like hypoalbuminemia, burns, trauma, liver cirrhosis, and cardiac surgeries that necessitate albumin therapies. This market analysis reveals that the demand for biologics and vaccines, combined with advancements in medical technology, is propelling market growth. Human serum albumin, known for its diverse medical applications such as fluid resuscitation and wound healing, leads the type segment, making it a significant part of the market report.
The therapeutics segment is at the forefront in applications due to albumin's vital role in various therapeutic processes. Business-to-business sales dominate the market, but the business-to-consumer segment is rapidly expanding due to its direct accessibility to end-users. This market share distribution highlights the industry's dynamics. Geographically, North America leads in revenue, supported by advanced healthcare infrastructure, with Asia-Pacific projected to witness the fastest growth due to increased healthcare spending and disease prevalence.
This industry analysis indicates continuous development in albumin applications in drug formulations and ongoing research as key factors for the robust expansion of this market. The market size and value segmentation across types, applications, sales channels, and regions provide a comprehensive market overview. For detailed market insights, including market forecast, market review, and market predictions, a comprehensive analysis is available. This market data is crucial for understanding the market trends and market segmentation that drive the global market.
Industry reports and market research highlight the industry outlook and industry trends, essential for stakeholders. The market leaders in this segment continue to innovate, ensuring the market outlook remains positive. For those seeking more detailed industry information, a report example and report pdf are available for further industry research. This industry sales data underscores the importance of market value and industry statistics in evaluating market growth.
